The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | New therapeutic options for tailored and selective treatment of multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, highlights that multiple myeloma treatment has become much more tailored and selective, which benefits the patients in the long-run. Techniques such as genetic profiling have allowed for optimization of therapy, which ensures treatment side-effects are reduced. Dr Richardson reflects on the long-term dangers of high dose melphalan therapy and enumerates new therapies for multiple myeloma. Besides the recent approval of 12 new drugs, therapies such as CAR T-cell therapy, bispecific T-cell engagers, antibody-drug conjugates (such as belantamab mafodotin), new antibodies (such as isatuximab) and novel agents (such as iberdomide, a cereblon E3 ligase modulator), seem promising for multiple myeloma patients. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Oncopeptides: service on advisory committees and research funding
